Molecular Partners AG Files 20-F Annual Report for Fiscal Year 2023

TL;DR

<b>Molecular Partners AG has submitted its 20-F annual report, providing a comprehensive overview of its financial and operational status for the fiscal year 2023.</b>

AI Summary

MOLECULAR PARTNERS AG (MOLN) filed a Foreign Annual Report (20-F) with the SEC on March 14, 2024. Molecular Partners AG filed its 20-F annual report for the fiscal year ending December 31, 2023. The company's primary business is in Biological Products (No Diagnostic Substances) under SIC code 2836. The filing covers the period from January 1, 2023, to December 31, 2023. Molecular Partners AG is incorporated in V8 and has its principal executive offices in Zurich-Schlieren, Switzerland. The report details financial information and business operations for the fiscal year 2023.

Why It Matters

For investors and stakeholders tracking MOLECULAR PARTNERS AG, this filing contains several important signals. This filing provides investors and stakeholders with crucial financial data, operational updates, and risk disclosures for Molecular Partners AG, enabling informed investment decisions. As a 20-F filing, it offers a detailed look into the company's performance and strategic direction, particularly relevant for international investors and those tracking the biotechnology sector.

Risk Assessment

Risk Level: medium — MOLECULAR PARTNERS AG shows moderate risk based on this filing. The company's financial health and future prospects are subject to the inherent risks of the biotechnology sector, including clinical trial outcomes and regulatory approvals, as detailed in the 20-F filing.

Analyst Insight

Investors should review the detailed financial statements and risk factors within the 20-F filing to assess Molecular Partners AG's current standing and future potential.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed period of report)
• 2024-03-14 — Filed As Of Date (Date the filing was submitted)
• 137 — Public Document Count (Number of documents in the filing)
• 001-40488 — SEC File Number (SEC registration number)

Key Players & Entities

• MOLECULAR PARTNERS AG (company) — Filer name
• 20-F (regulator) — Form type
• 2024-03-14 (date) — Filed as of date
• 2023-12-31 (date) — Conformed period of report
• 0001745114 (company) — Central Index Key
• 2836 (industry) — Standard Industrial Classification
• WAGISTRASSE 14 (address) — Business address street 1
• Z?RICH-SCHLIEREN (location) — Business address city

FAQ

Industry Context

Molecular Partners AG operates within the biotechnology sector, focusing on the development of novel therapeutic proteins.

Regulatory Implications

As a foreign private issuer, Molecular Partners AG files an annual report on Form 20-F with the U.S. Securities and Exchange Commission (SEC).

What Investors Should Do

1. Review the full 20-F filing for detailed financial statements and management discussion.
2. Analyze the risk factors section to understand potential challenges and uncertainties.
3. Compare the 2023 financial performance with previous years to identify trends.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 20-F filing.
• 2024-03-14: Filing Date — Date the 20-F report was officially submitted to the SEC.

Year-Over-Year Comparison

This filing represents the annual disclosure for the fiscal year 2023, providing updated financial and operational information compared to previous filings.

Filing Documents

• moln-20231231.htm (20-F) — 2839KB
• a11articlesofincorporation.htm (EX-1.1) — 334KB
• a46molecularpartners-resea.htm (EX-4.6) — 606KB
• a416psuplan2024_employeeso.htm (EX-4.16) — 128KB
• a417psuplan2024_formanagem.htm (EX-4.17) — 110KB
• a424rsuplan2024.htm (EX-4.24) — 103KB
• a121section302certification.htm (EX-12.1) — 8KB
• a122section302certification.htm (EX-12.2) — 8KB
• a131section906certification.htm (EX-13.1) — 7KB
• a151auditorconsent.htm (EX-15.1) — 2KB
• a971molecularpartners-dodd.htm (EX-97.1) — 36KB
• moln-20231231_g1.jpg (GRAPHIC) — 527KB
• moln-20231231_g2.jpg (GRAPHIC) — 249KB
• moln-20231231_g3.jpg (GRAPHIC) — 178KB
• moln-20231231_g4.jpg (GRAPHIC) — 320KB
• moln-20231231_g5.jpg (GRAPHIC) — 60KB
• moln-20231231_g6.jpg (GRAPHIC) — 52KB
• moln-20231231_g7.jpg (GRAPHIC) — 81KB
• 0001745114-24-000003.txt (&nbsp;) — 16901KB
• moln-20231231.xsd (EX-101.SCH) — 107KB
• moln-20231231_cal.xml (EX-101.CAL) — 96KB
• moln-20231231_def.xml (EX-101.DEF) — 344KB
• moln-20231231_lab.xml (EX-101.LAB) — 813KB
• moln-20231231_pre.xml (EX-101.PRE) — 599KB
• moln-20231231_htm.xml (XML) — 2082KB

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 168 Item 12.

Description of Securities Other than Equity Securities

Description of Securities Other than Equity Securities 169 A. Debt Securities 169 B. Warrants and Rights 169 C. Other Securities 169 D. American Depositary Shares 170 PART II Item 13. Defaults, Dividend Arrearages and Delinquencies 172 Item 14. Material Modifications to the Rights of Security Holders 172 Item 15.

Controls and Procedures

Controls and Procedures 172 Item 16A. Audit Committee Financial Expert 173 Item 16B. Code of Ethics 173 Item 16C. Principal Accountant Fees and Services 173 Item 16D. Exemptions from the Listing Standards for Audit Committees 174 Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers 174 Item 16F. Change in Registrant's Certifying Accountant 174 Item 16G. Corporate Governance 175 Item 16H. Mine Safety Disclosure 175

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 175 Item 16J. I nsider Trading Policies 175 Item 16K. Cybersecurity 176 PART III Item 17.

Financial Statements

Financial Statements 178 Item 18.

Financial Statements

Financial Statements 178 Item 19. Exhibits 179 5 6 INTRODUCTION Unless the context requires otherwise, references in this Annual Report on Form 20-F to the "Company," "Molecular Partners," "we," "us" and "our" refer to Molecular Partners AG and its wholly-owned subsidiary. We own trademark registrations for "Molecular Partners " and "DARPin " in Switzerland, the European Union, the United States and Japan. All other trade names, trademarks and service marks of other companies appearing in this Annual Report on Form 20-F are the property of their respective holders. Solely for convenience, the trademarks and trade names in this Annual Report on Form 20-F may be referred to without the and symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend to use or display other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies . We present our consolidated financial statements in CHF and in accordance with IFRS Accounting Standards ("IFRS") as issued by the International Accounting and Standards Board . None of the financial statements were prepared in accordance with generally accepted accounting principles in the United States. The terms "dollar," "USD" or "$" refer to U.S. dollars and the terms "Swiss Francs" or "CHF" refer to the legal currency of Switzerland. Unless otherwise indicated, all references to currency amounts in this Annual Report on Form 20-F are in U.S. dollars. We have made rounding adjustments to some of the figures included in this Annual Report on Form 20-F. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 20-F contains forward-looking statements within the m

Identity of Directors, Senior Management and Advisers

Item 1. Identity of Directors, Senior Management and Advisers. Not applicable.

Offer Statistics and Expected Timetable

Item 2. Offer Statistics and Expected Timetable. Not applicable.

Key Information

Item 3. Key Information. A. [Reserved] B. Capitalization and Indebtedness Not applicable. C. Reasons for the Offer and Use of Proceeds Not applicable. D. Risk Factors Investing in the ADSs involves a high degree of risk. You should carefully consider the risks and uncertainties described below and the other information in this Annual Report on Form 20-F before making an investment decision. Our business, financial condition or results of operations could be adversely affected if any of these risks occurs, and as a result, the market price of the ADSs could decline and you could lose all or part of your investment. This report also contains forward-looking statements that involve risks and uncertainties. See "Special Note Regarding Forward-Looking Statements." Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors. 11 Risks Related to Our Financial Position and Need for Additional Capital We have incurred significant losses since our inception, we expect to incur losses in future periods and may not maintain profitability in the upcoming years. We may need substantial additional funding in order to complete the development and commercialization of our product candidates. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development or research operations. Since our inception, we have incurred significant operating losses, including negative net results, attributable to shareholders. As of December 31, 2023, we had cumulative losses of CHF 191.8 million. For the year ended December 31, 2023 we recorded negative net result, attributable to shareholders of CHF 62.0 million and for the year ended December 31, 2022, we incurred positive net result, attributable to shareholders of CHF 117.9 million. The positive result in 2022 was largely driven by the January 2022 payment of CHF 150 million by Novar

View Full Filing

View this 20-F filing on SEC EDGAR